{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-22-000043","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.571405+00:00","generated_at":"2026-06-24T04:43:24.525722+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurocrine Q2 INGREZZA sales $350M (+32%), raises FY guidance to $1.35-1.40B; essential tremor Phase 2a fails","bullets":["GAAP net loss $16.9M ($0.18 loss per diluted share) vs net income $42.3M in Q2 2021, largely due to $70M debt extinguishment loss.","Non-GAAP net income $82.1M ($0.84 EPS) vs $70.1M ($0.72); INGREZZA net product sales $350M, up 32% YoY.","Raised 2022 INGREZZA net product sales guidance to $1.35-1.40B from prior $1.30-1.35B; GAAP R&D guidance $415-450M.","Phase 2a study of NBI-827104 in essential tremor did not meet endpoints; company discontinues development in that indication.","Received $20M milestone from MTPC for DYSVAL launch in Japan; FDA cleared IND for NBI-1117568 (M4 agonist for schizophrenia) Phase 2."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-22-000043","json":"https://secwatch.observer/filing/0000914475-22-000043.json","markdown":"https://secwatch.observer/filing/0000914475-22-000043.md","text":"https://secwatch.observer/filing/0000914475-22-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000043/0000914475-22-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000043/nbix-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:43:24.525722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}